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Abstract 
Pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year 
survival rate lower than 5%.  In the United States, this disease is the fourth leading cause of 
death and represents 6% of all cancer related deaths. Gemcitabine, the current standard first-
line treatment offers marginal benefits to patients in terms of symptom control and 
prolongation of life. Since 1996, about 20 randomized phase III trials have been performed to 
improve the efficacy of gemcitabine with little success regarding a significant improvement in 
survival outcomes. The need for novel therapeutic strategies such as target therapy is obvious. 
Monoclonal antibodies have finally come of age as therapeutics and several molecules are 
now approved for cancer therapies. This review aims at giving a general view on the clinical 
results obtained so far by antibodies for the treatment of pancreatic cancer and describes the 
most promising avenues toward a significant improvement in the treatment of this frustrating 
disease. 
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Introduction 
Pancreatic cancer  
Pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year 
survival rate lower than 5%.  Although accounting for only 3% of all cancers, this disease is 
the fourth leading cause of death and represents 6% of all cancer related deaths. In the United 
States, the overall incidence is about 8-10 cases per 100,000 persons/year and rises slowly 
over the years (1). Pancreatic cancer remains one of the most difficult to treat due to late 
initial diagnosis and to intrinsic resistance to conventional treatments.  About 50% of patients 
have distant disease at the time of diagnosis (locally advanced stage) and in 40% the tumor 
has spread (metastatic stage). Risk factors have been identified (2), molecular pathogenesis 
has been elucidated, but advances in early detection and efficient treatments remain rather 
disappointing despite tremendous efforts. The majority of pancreatic tumors (95%) is 
adenocarcinoma and mainly develops from exocrine cells. They are characterized by an 
aggressive behavior with a fast progression rate that makes them highly metastatic, by a dense 
fibrotic stroma surrounding a minor population of cancerous cells and by an early and 
vascular invasive growth. This reactive stroma is composed of extracellular matrix proteins 
(collagen, fibronectin), myofibroblastic pancreatic stellate cells, immune cells, cytokines, 
growth factors, proteases and vessels.  
Current treatments 
There is consensus on the fact that surgical removal of the tumor represents the best option for 
pancreatic cancer treatment; to be resectable, tumors need to be small and strictly localized to 
pancreas without invasion into surrounding organs and evidence of metastasis. However, only 
15-20% of all patients are candidates for potentially curative surgery. Depending on the tumor 
localization, pancreaticoduodenectomy, distal or total pancreatectomy can be performed. 
However, even with an optimal curative surgery, metastases often occur. Median survival 
time without evidence of recurrent disease is 21.2 months after resection (3).  
For locally advanced or metastatic disease, treatment is still palliative rather than curative, and 
chemotherapy remains the only option. Since its approval in 1997, gemcitabine is the current 
standard first-line treatment. It was shown by Burris and colleagues (4) to improve median 
disease-free survival and overall survival (OS) rate at 5 years.  Since 1996, about 20 
randomized phase III trials have been performed to improve the efficacy of gemcitabine with 
little success regarding a significant improvement in survival outcomes (for review see (5-7)). 
A small clinical benefit is evidenced for the erlotinib/gemcitabine and platinum/gemcitabine 
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combinations but it must be balanced by increased toxicity. Up to now, the only combination 
approved by FDA is the gemcitabine/erlotinib combination (Tarceva®) which increased the 
median overall survival from 6 to 6.4 months (8, 9).  
 
New potential targets 
Advances in the understanding of pancreatic cancer biology and of the mechanisms by which 
it eludes conventional cytotoxic therapies should lead to the identification of new potential 
targets. Cancer stem cells (CSC) might be one of them. Tumors are constituted by 
differentiated cells that have limited proliferative potential and by a small subset of cancer 
cells responsible for tumor initiation and propagation (10, 11). In pancreatic cancer, CSC 
represent 0.2 to 0.8% of all cancer cells and they are characterized by cell surface markers 
CD44, CD24, ESA (epithelial specific antigen) (12). CSC have been shown to be resistant to 
conventional chemotherapy and radiation (13), which might explain the poor therapeutic 
results of current therapies. The contribution of tumor/stroma interactions in pancreatic cancer 
progression has also been recently emphasized (14, 15). Promising results in a phase II trial 
have been obtained by combining gemcitabine with nab-paclitaxel (16). This compound 
which is an anti-mitotic agent increased the potency of gemcitabine by altering the stroma 
surrounding the tumor.  
Thus, the need for novel therapeutic strategies such as target therapy in pancreatic cancer 
patients is obvious. Recent years have seen the approval of several therapeutic antibodies for 
cancer therapy (Table 1), some of them leading to very significant therapeutic effects (17). 
Disappointments met with the first murine therapeutic molecules that were rapidly eliminated 
by the patient’s immune system and that were not interacting properly with human receptors 
of the patient’s effector cells have been replaced with significant clinical outcomes  achieved 
by chimeric (human IgG bearing murine variable domains), humanized (human IgG bearing 
murine hypervariable loops) and fully human antibodies (17). Therapeutic antibodies have 
been shown to rely on various modes of action, including direct blocking of a ligand or a 
receptor, induction of apoptosis by receptor clustering, complement-dependent cytotoxicity, 
or cell-mediated cytotoxicity/phagocytosis. The last generation of therapeutic antibodies has 
been engineered to strongly interact with activating receptors such as FcRIIIA expressed on 
NK cells. Modifications have targeted some residues of the Fc fragment involved in the 
interaction with Fc receptors, or the nature of the Fc glycosylation shown to greatly influence 
the affinity of the receptors for the IgG. More recently, bispecific antibodies capable of 
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simultaneously binding to a tumor antigen and to CD3 on T cells and thereby redirecting 
polyclonal T cells to tumor cells have led to exciting clinical results (18, 19). 
The aim of this paper is to review the most recent studies involving the use of antibodies for 
the treatment of pancreatic cancer. 
1. Clinical trials involving antibodies 
1.1. Angiogenesis 
Vascular endothelial growth factor (VEGF)  
Angiogenesis provides the required substrates for tumor growth and dissemination. Targeting 
angiogenesis is attractive because in theory it can reduce cancer progression. VEGF-A (or 
VEGF) is the predominant member of the VEGF family. VEGF receptor is similar to EGFR 
because after binding to its ligand, VEGF receptor forms a dimer, and the tyrosine kinase 
becomes autophosphorylated and amplifies the initial signal by activating the intracellular 
pathways, such as MAPK and PI3K (20). VEGF exerts most of its neoangiogenic effects 
through VEGF-R2 (21). VEGF is expressed in 88% to 93% of the patients with pancreatic 
adenocarcinoma (22). Moreover, VEGF presence in tumor samples correlates with tumor size, 
and is also a predictor of early recurrence after surgery, development of liver metastasis, poor 
prognosis, and cancer-related death (23). 
Bevacizumab is a recombinant humanized anti-VEGF-A monoclonal antibody that prevents 
binding to both VEGFR (Table 1). This antibody has proven clinical benefit in metastatic 
colon, breast, and non-small cell lung cancer. Bevacizumab decreases lymphangiogenesis and 
neovascularization in vivo and is expected to increase the delivery of chemotherapy to the 
tumor in pancreatic cancer.  Kindler and colleagues reported the results of a phase II trial of 
bevacizumab plus gemcitabine in 52 patients with metastatic pancreatic cancer. Partial 
responses were observed in 21% of patients, the median survival time was 8.8 months, and 
the 1-year survival rate was 29% (24). The major side effect with bevacizumab therapy in 
pancreatic cancer is bleeding and perforation. Therefore, it was not recommended in patients 
with tumors invading the duodenum or other organs. These data prompted the CALGB to 
conduct a double-blind, placebo-controlled randomized phase III trial (CALGB 80303) of 
gemcitabine plus bevacizumab versus gemcitabine plus placebo in 602 advanced pancreatic 
cancer patients. Gemcitabine was given in the standard fashion and bevacizumab was given at 
a dose of 10 mg/kg on days 1 and 15 of each 28-day cycle. Unexpectedly, the median OS 
times were 5.7 months and 6.0 months for gemcitabine plus bevacizumab and gemcitabine 
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plus placebo, respectively (25). Finally a phase III Trial of bevacizumab in combination with 
gemcitabine and erlotinib involving 607 patients with metastatic pancreatic cancer 
demonstrated that the addition of bevacizumab to gemcitabine-erlotinib does not lead to a 
statistically significant improvement in OS in patients, although progression free survival was 
significantly longer in the bevacizumab group compared with placebo (26). 
Unfortunately, it appears that bevacizumab does not lead to clinical benefits for pancreatic 
cancer treatment, probably because other pro-angiogenic factors including insulin-like growth 
factor-I, hepatocyte growth factor, fibroblast growth factor, platelet-derived growth factor, 
and TGF- are often overexpressed by pancreatic cancer cells. 
Integrin 5β1  
Integrins form a superfamily of widely expressed transmembrane glycoprotein receptors for 
extracellular matrix ligands, such as fibronectin, vitronectin, laminin, collagens, and other 
plasma membrane proteins, and are involved in the regulation of a broad variety of cellular 
processes, including embryogenesis, inflammation, bone metabolism, apoptosis, cell 
proliferation, angiogenesis, and tumor metastasis. Integrin alpha5beta1, the principal 
fibronectin receptor, is an important survival factor, playing a key role in angiogenesis. 
Endothelial cell expression of the 51 integrin and its ligand fibronectin are both up-
regulated during tumor angiogenesis (27). Volociximab, a high-affinity IgG4 chimeric 
monoclonal antibody, has lead to a very efficient apoptosis of vascular endothelial cells, 
angiogenesis and tumor growth inhibition in preclinical studies, independently of the VEGF 
pathway (28). Volociximab is currently being tested in a phase II study in combination with 
gemcitabine in 40 patients with metastatic pancreatic cancer. Preliminary results (ASCO 2008 
Gastrointestinal Cancers Symposium, abstract 142) indicate 3 partial remissions and 17 stable 
diseases. The treatment was well tolerated and these results are thus encouraging. 
1.2. Tumor targeting 
Epidermal growth factor receptor (EGFR) 
The EGFR, also known as ErbB1 or HER1, is a 170 kDa protein belonging to the four-
member ErbB1-4 family of transmembrane tyrosine kinase growth factor receptors. Upon 
binding to a number of ligands conformational alterations occur in the single chain receptor, 
allowing dimerization or oligomerization with other EGFR molecules or other members of the 
ErbB family, leading to autophosphorylation and signal transduction. EGFR is expressed in 
30% to 89% of pancreatic cancers assayed by immunohistochemistry techniques (29, 30).  
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Cetuximab is an anti EGFR therapeutic antibody already approved for the treatment of 
colorectal cancer (Table 1). This antibody has also been investigated in pancreatic cancer, in 
combination with the standard gemcitabine agent. In a phase II study with chemotherapy 
naïve patients with advanced disease, 41 patients with EGFR immunostain-positive tumors (6 
locally advanced, 34 metastatic) were treated with cetuximab (initial dose 400 mg/m2, 
followed by 250 mg/m2 weekly) and gemcitabine. Five patients (12.5%) achieved a partial 
response and 26 patients (63.4%) had stable disease. The median time to progression was 3.8 
months, and the median OS duration was 7.1 months. The 1-year survival rate of 31.7% 
compared favorably to 18% with gemcitabine alone in historical series. The combination was 
well tolerated with the most commonly reported toxicities of all grades as follows: rash 
(87.8%), nausea (61.0%), weight loss (58.5%), and diarrhea (53.7%) (31). This small but 
significant improvement warranted further studies and two trials were launched. The SWOG 
S0205 study was a randomized phase III trial of gemcitabine with or without cetuximab in 
766 patients with locally advanced or metastatic pancreatic adenocarcinoma. The data, 
presented in 2007, did not evidence a statistically significant difference in progression free 
survival (PFS) (3 vs 3.5 months, p = 0.14), and OS duration (6 vs 6.5 months, p = 0.058), in 
the gemcitabine alone vs gemcitabine and cetuximab groups, respectively (32). The second 
study (ECOG) was a randomized phase II trial, in which 87 eligible patients with metastatic 
pancreatic cancer were randomized to the Murren regimen of docetaxel and irinotecan with or 
without cetuximab. Unexpectedly, the patients treated with cetuximab had shorter median 
survival duration (5.3 months) compared to the placebo group (6.5 months). A very short 
post-progression survival was observed in the cetuximab arm, not well explained by the data. 
The toxicity of this regimen was high, even without cetuximab. Grade 3 or 4 diarrhea was 
observed in 47% of patients in the three drug arm and the rate of treatment-related death was 
4% (33). Thus, unfortunately, no significant improvements could be demonstrated using 
cetuximab. Of note, another anti-EGFR antibody, matuzumab, has demonstrated some 
activity in clinical trials. A phase I study assessed the safety and potential benefit of combined 
treatment with matuzumab and standard-dose gemcitabine (34). Seventeen chemotherapy-
naive advanced pancreatic adenocarcinoma patients received escalating doses of matuzumab 
(400 mg weekly, 800 mg biweekly, or 800 mg weekly) and gemcitabine. Severe treatment-
related toxicities were limited to grade 3 neutropenia, leucopenia, and decreased white blood 
cell count. Common study drug-related adverse events were skin toxicities and fever. 
Matuzumab inhibited phosphorylated EGFR and affected receptor-dependent signaling and 
transduction; effects were seen even in the lowest-dose group. Partial response (PR) or stable 
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disease occurred in eight of 12 evaluated patients (66.7%), with three PRs among six 
evaluated patients in the group receiving 800 mg weekly. Matuzumab was thus well tolerated 
and the combination may have enhanced activity. Panitumumab is a fully human anti-EGFR 
that prevents EGF and TGF- from binding to the receptor (Table 1). This antibody has 
yielded exciting preclinical data, including the complete eradication of established human 
tumors (derived from the human vulvar epidermoid carcinoma cell line A431) as large as 1.2 
cm
3 
(35). A phase II clinical trial comparing gemcitabine plus erlotinib with or without 
panitumumab is currently ongoing in the USA (NCT00550836). 
 
Human Epidermal growth factor Receptor 2 (HER2)  
HER2 (or ErbB2) is another member of the EGFR family. HER2 is involved in signal 
transduction pathways leading to cell growth and differentiation, and is overexpressed in a 
number of cancers, including breast and pancreatic cancer. Up to 26% of pancreatic tumor 
specimens express HER2 as shown by immunohistochemistry (36). Trastuzumab is a 
neutralizing humanized antibody directed against the extracellular domain of the HER2 
receptor (Table 1). The therapeutic effect of trastuzumab is well documented in breast cancer 
and has been ascribed to cell cycle arrest and induction of apoptosis as well as induction of 
antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells 
(37). Based on this rational and on several encouraging pre-clinical results, a phase I clinical 
trial enrolling 34 patients with metastasized HER2 overexpressing (grade 2-3) pancreatic 
cancer was launched. A combination of trastuzumab and gemcitabine resulted in partial 
response rates of 6%, and 41% of patients showed a >50% reduction of the tumor marker 
CA19-9 (38). A modest improvement of the median survival in patients with metastatic 
pancreatic cancer suggested there may be a modest benefit of trastuzumab treatment for some 
patients. A larger phase II trial combining trastuzumab and capecitabine should start soon 
(39).   
Interestingly, a combination of anti-HER1 and anti-HER2 antibodies was tested in preclinical 
studies and demonstrated a significant improvement of survival and tumor regression in mice 
treated with trastuzumab plus cetuximab in first and second-line treatments, compared with 
gemcitabine. These results warrant further clinical trials (40). 
Mesothelin  
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Mesothelin is a differentiation antigen whose expression in normal human tissues is limited to 
mesothelial cells lining the pleura, pericardium and peritoneum (41).  The mesothelin gene 
encodes a precursor protein of 71 kDa that is processed to a 31 kDa shed protein called 
megakaryocyte potentiating factor (MPF) and a 40 kDa fragment, mesothelin, that is attached 
to the cell membrane by a glycosyl-phosphatidylinositol (GPI) anchor. Mesothelin binds the 
mucine MUC-16, also called CA-125 (42), but little is known about its function.  It has been 
shown that mesothelin is highly expressed in several human cancers, including virtually all 
mesotheliomas and pancreatic adenocarcinomas, and approximately 70% of ovarian cancers 
and 50% of lung adenocarcinomas. Argani and colleagues were the first to show mesothelin 
expression in pancreatic ductal adenocarcinoma but not in normal pancreas (43). In addition, 
mesothelin mRNA expression was present in 4 of 4 resected primary pancreatic cancers and 
all 60 resected primary adenocarcinomas were mesothelin positive as shown by 
immunohistochemistry. These results were confirmed by Hassan and colleagues who showed 
that mesothelin was expressed in all 18 cases of pancreatic adenocarcinomas examined but 
absent in normal pancreas and in chronic pancreatitis (44). Mesothelin is also highly 
expressed in other adenocarcinomas of the biliary tree such as gallbladder cancer and tumours 
of the common bile duct (45). This tumor marker is being evaluated for targeted therapy.  
SS1P is a recombinant immunotoxin consisting of a mouse anti-mesothelin disuldide-
stabilized Fv linked to a truncated Pseudomonas exotoxin (dsFv-PE38) that mediates cell 
killing upon internalization. Pre-clinical studies have shown that SS1P is cytotoxic to cell 
lines expressing mesothelin and causes complete regression of mesothelin expressing tumour 
xenografts in nude mice (46).  This construct was further tested in phase I clinical trial. Out of 
the 34 patients treated (20 mesothelioma, 12 ovarian cancer and 2 pancreatic cancer) 4 had 
minor response and 19 had stable disease including complete resolution of ascites in two 
patients (47). The immunotoxin was well tolerated and led to some clinical resulted, 
warranting further clinical trials. 
MORAb-009 is a high-affinity chimeric (mouse/human) IgG1 with high affinity and 
specificity for mesothelin. The heavy and light chain variable regions of mouse anti-
mesothelin scFv (obtained by panning on mesothelin-positive cells a phage display library 
made from an immunized mouse) were grafted with human IgG1 and  constant regions. 
MORAb-009 was shown to prevent adhesion of mesothelin-bearing tumor cells to MUC16 
positive cells and to elicit cell-mediated cytotoxicity on mesothelin-bearing tumor cells. 
Treatment that included MORAb-009 in combination with chemotherapy led to a marked 
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reduction in tumor growth in nude mice compared to chemotherapy or MORAb-009 treatment 
alone (48). This antibody is now being evaluated in clinical trials. A phase I study of MORab-
009 on 24 mesothelioma, pancreatic and ovarian cancer patients gave encouraging results. 
MORAb-009 was well tolerated and 6 subjects demonstrated stable disease warranting 
additional therapy (49). Given the favorable safety profile and possibility of clinical benefit, a 
phase II study of the efficacy of MORAb-009 with gemcitabine in unresectable pancreatic 
cancer is underway. 
Carcinoembryonic antigen (CEA, CEACAM5)  
Carcinoembryonic antigen (CEA), a glycoprotein, is a tumor-associated antigen and elevated 
levels are detected in the cell membrane of tumors derived from epithelium. CEA is 
overexpressed in over 90% of pancreatic cancers (50). Binding of antibodies to CEA has been 
shown to inhibit cell migration, cell invasion, cell adhesion and to have anti metastatic effect 
in vivo (51). In a phase I/II clinical trial, Sultana and colleagues have enrolled 25 patients to 
assess the safety and efficacy of I
131
-labelled anti-CEA chimeric (sheep/human) antibody 
KAb201 in patients with unresectable pancreatic adenocarcinoma (52). In this approach based 
on the use of a monoclonal antibodies conjugated with radionuclides, the radiation component 
has a bystander effect, i.e. killing of adjacent unbound cells, while lessening toxicity to 
normal tissues. The results demonstrated tumor targeting, with hematological toxicity of 
varying degrees. Survival and efficacy data was comparable to the median survival and 
efficacy seen with single agent gemcitabine. An antigenic responses directed to the chimeric 
antibody was observed and might constitute a limitation for repeated dosing. 
Insulin-like Growth Factor 1 Receptor (IGF-1R)  
Cixutumumab (IMC-A12) is a fully human monoclonal antibody (IgG1) against type 1 insulin 
like growth factor receptor (IGF-1R). The IGF-1R and its ligands IGF-1 and IGF-2 have been 
implicated as playing key roles in the development, maintenance, and progression of cancer 
(53). IGF-1R signaling is known to activate both the PI3K/Akt and the MAP kinase pathways 
leading to increased tumor cell survival and proliferation, respectively. By blocking this 
signaling, cixutumumab has demonstrated encouraging results in preclinical studies, with 
significant growth inhibition of breast, renal, and pancreatic tumors, and a marked increase in 
apoptotic tumor cells in antibody-treated animals (54). A phase I/II clinical trial is currently 
comparing the efficiency of gemcitabine and erlotinib with or without cixutumumab for the 
treatment of patients with metastatic pancreatic cancer (NCT00617708). 
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AMG 479 is also a fully human monoclonal IgG1 antibody that binds IGF-1R without cross-
reacting with the closely related insulin receptor. AMG 479 has been shown to inhibit binding 
of IGF-1 and IGF-2 to the receptor (55). As a single agent, AMG 479 strongly inhibited the 
growth of pancreatic carcinoma xenografts, and long-term treatment was associated with 
reduced IGF-IR signaling activity and expression. The combination of AMG 479 with 
gemcitabine resulted in additive inhibitory activity both in vitro and in vivo. A phase II study 
of AMG 479 as single therapy in advanced carcinoid and pancreatic neuroendocrine tumors is 
currently on going (NCT01024387). 
 
2. Pre-clinical studies 
Several other tumor targets have been explored as marker for antibody therapy of pancreatic 
cancer.  
Nonspecific cross-reacting antigen (NCA, CEACAM6) 
CEACAM6 (CD66c) is an integral member of the CEA family. It is a cell surface 
glycoprotein composed of an extracellular region containing three immunoglobulin-like 
domains (344 residues) and linked to the plasma membrane via a glycophosphoinositol-
anchor. CEACAM6 is capable of homophilic and/or heterophilic adhesion to other CEACAM 
family members (56). CEACAM6 is expressed on normal human epithelial and myeloid cells 
but the level of expression is 1 to 2 log lower compared with expression in malignant tissue 
(57). Several gene expression profiling studies on pancreatic ductal adenocarcinoma (PDA) 
cell lines (58, 59) and human PDA biopsy samples (60, 61) have shown a 20- to 25-fold 
overexpression of CEACAM6 compared with normal pancreatic ductal epithelial cells (58, 
61). CEACAM6 is also overexpressed in several other epithelial carcinomas (colon, breast, 
ovarian and non–small cell lung cancers) (57). Based on these data, CEACAM6 appears as an 
attractive pancreatic tumor marker.  However, expression of CEACAM6 protein has been 
noted in a variety of normal human tissues, including granulocytes and antigen-dependent 
toxicity cannot be easily tested in preclinical model since rodents do not express CEACAM6. 
A recent interesting preclinical study has evaluated the potential of an immunoconjugate 
between a chimeric (mouse/human) anti-CEACAM6 IgG and an anti-mitotic agent, 
maytansinoid (DM1), in Cynomolgus macaques (62). The authors first confirmed the 
expression of CEACAM6 in > 90% of invasive pancreatic adenocarcinomas as well as in 
intraepithelial neoplastic lesions by tissue macroarrays and obtained a marked tumor growth 
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inhibition in xenografted mice. As expected, the treatment induced neutropenia in macaques, 
as a result of antigen-dependent toxicity. However this phenomenon was fully reversible and 
the authors observed a repopulation from the pool of CEACAM6-negative, lineage-committed 
progenitors in a time span shorter than typically seen after bone marrow ablation in the course 
of conventional, non-targeted cytotoxic chemotherapy. Beside this rapid but reversible 
neutrophils depletion, no adverse effects were seen, which encourages further studies of this 
immunoconjugate. 
CEACAM6 has also been targeted in another preclinical study for the treatment of pancreatic 
ductal adenocarcinoma. The authors have produced a humanized anti-CEACAM6 scFv 
fragment and PEGylated the fragment through the introduction of a cysteine in the linker to 
increase serum half life (63). In vivo, the fragment inhibits tumor growth in a murine 
xenograft model, through inhibition of angiogenesis and proliferation. It was shown to 
specifically induce targeted tumor cell apoptosis without dependence on antibody-dependent 
cellular cytotoxicity, complement dependent cytotoxicity, or conjugation with a cytotoxic 
agent. The proposed mode of action was high affinity binding to CEACAM6, which enhances 
the disruption of domain 1 homophilic dimer with consequent functional inhibition of 
CEACAM6, known to play an important role in apoptosis resistance in conditions where cells 
lose contact with the extra cellular matrix (64). These promising results justify clinical trials.             
Epithelial cell adhesion molecule (EpCAM)  
EpCAM is a glycosylated, 30- to 40-kDa type I membrane protein, which is expressed in a 
variety of human epithelial tissues, cancers, and progenitor and stem cells. EpCAM is 
comprised of an extracellular domain with epidermal growth factor (EGF)- and thyroglobulin 
repeat-like domains, a single transmembrane domain, and a short 26-amino acid intracellular 
domain. EpCAM in normal cells is predominantly located in intercellular spaces where 
epithelial cells form very tight junctions. It has, therefore, been speculated that EpCAM on 
normal epithelia is sequestered and, therefore, much less accessible to antibodies than 
EpCAM in cancer tissue, where it is homogeneously distributed on the cancer cell surface. 
Moreover, EpCAM is expressed on essentially all human adenocarcinoma, on certain 
squamous cell carcinoma, on retinoblastoma, and on hepatocellular carcinoma (65). 
Importantly, EpCAM is part of the signature of cancer-propagating cells in numerous solid 
tumors and of normal progenitor and stem cells (11, 66). Moreover, EpCAM is apparently 
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needed to maintain distinct cancer cell attributes (67) and, potentially, cancer stem cell 
phenotype as well. 
Recently, several studies using various formats of bispecific antibodies (bsAbs) to retarget T 
cells to tumor cells have yielded outstanding results in cancer therapy studies (18, 19).  
Interestingly, several of these molecules target EpCAM. Catumaxomab, a EpCAM x CD3 
bsAb represents the first success of this new class of therapeutic antibodies as it was recently 
approved for the intraperitoneal treatment of patients with EpCAM positive malignant ascites 
(68). In clinical trials, this molecule could lead to very clear clinical results, including a 
reduction of EpCAM-positive malignant cells in ascites by up to 5 logs (69) and the induction 
of a long term anti cancer immunity (70). The efficiency of this new molecule for pancreatic 
cancer should soon be assessed. 
MT-110 is another EpCAM x CD3 bsAb that can induce potent redirected lysis of target 
antigen-expressing cells at pico to femtomolar concentrations, which is accompanied by 
highly conditional T cell activation. Redirected lysis involves formation of a cytolytic 
synapse, possibility of serial lysis at very low effector-to-target (E:T) ratios, and is no longer 
depends on MHC class I expression or co-stimulatory molecules (71, 72). This molecule is 
also expected to be tested soon for pancreatic cancer treatment. 
Finally, a third EpCAM x CD3 bsAb is yielding promising results for pancreatic cancer 
treatment. HEA125 x OKT3, a hybrid-hybridoma-derived murine bispecific antibody, has 
recently been investigated in preclinical studies using BxPC-3 pancreatic carcinoma 
xenografts in NOD SCID mice (73). The bsAb could significantly retard growth of xenografts 
in vivo, and was shown to increase duration of the contact between migrating lymphocytes 
and tumor cells, and to stimulate secretion of effector cytokines from non-stimulated PBMCs 
in the presence of EpCAM-bearing tumour cells in vitro. 
Mucin 1 (MUC-1) 
MUC-1 is a mucin expressed by >85% of invasive pancreatic adenocarcinomas, including 
early stage I disease and the precursor lesions, pancreatic intraepithelial neoplasia and 
intraductal papillary mucinous neoplasia (74). PAM-4, a murine anti-MUC-1 IgG, targets an 
epitope of MUC-1 which is absent from normal and inflamed pancreatic tissues, as well as 
from most other malignant tissues (75). Preclinical studies demonstrated that PAM-4 was able 
to target pancreatic cancer with high specificity, achieving high concentrations at the tumor 
site using xenografted athymic nude mice. More recently, TF10, an anti-MUC-1 x HSG bsAb 
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was derived from this mAb. This bsAb can be used in pretargeted approaches, in which the 
bsAb is first injected and is allowed to accumulate in the tumor before injecting, in a second 
step, a radiolabeled hapten (
111
In-HSG) that is captured by the bsAb at the tumor site. This 
method can lead to very high tumor to normal tissues contrasts. When compared with its 
parental mAb in studies conducted in nude mice bearing CaPan1 human pancreatic cancer 
xenografts, TF10 led to much greater tumor/blood ratios of 
111
In-HSG (1,000:1 at 3 hours) 
compared to 
111
In-PAM4-IgG (5:1 at 24 hours) (76). The high therapeutic potential of this 
approach should thus soon be tested in the clinic. 
Death Receptor 5 (TRAIL-R2)  
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to death receptors 4 
and 5 (DR4, DR5) to transduce apoptotic signals. TRAIL receptors are increased in the 
membrane of cancer cells. More than 50% of cancer cell lines tested in vitro are TRAIL-
susceptible.  Brain, lung, pancreatic, liver, ovary, rectum, cervix, testes, thyroid, stomach, and 
laryngopharynx cancers frequently overexpress DR4 and DR5 (77). However, the ability of 
soluble human TRAIL to induce apoptosis of normal human hepatocytes in vitro has raised 
questions regarding the potential usefulness of this agent in cancer therapy. TRA-8, an anti-
human DR5 monoclonal antibody induces apoptosis of most (TRAIL)-sensitive tumor cells 
both in vitro and in vivo. However, unlike TRAIL, it does not induce apoptosis in normal 
hepatocytes (77). In animal models, TRA-8 produced synergistic cytotoxicity in combination 
with gemcitabine or irinotecan through enhanced caspase activation (78-80). These findings, 
with substantial inhibition of tumor growth in a mouse pancreatic cancer xenograft model 
receiving combination therapy, are encouraging for anti-death receptor therapy in the 
treatment of pancreatic cancer. Tigatuzumab, the humanized IgG1 monoclonal antibody 
derived from TRA-8 is ongoing phase-I clinical trials at the moment (81). 
Conatumumab (AMG 655) is a fully human monoclonal agonist antibody (IgG1) to human 
DR5. This mAb can also induce apoptosis via caspase activation and could inhibit tumor 
growth in colon (Colo205 and HCT-15), lung (H2122) and pancreatic (MiaPaCa2/T2) 
xenograft models (82). These results suggest that conatumumab is a potential therapeutic 
agent for treating patients with multiple tumor types, including pancreatic tumors. Clinical 
trials are expected for soon. 
Other targets of interest 
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Human Claudin-4 (CLDN4) is a tetraspanin transmembrane protein consisting of 209 amino 
acids (aa) belonging to the CLDN family which play an important role in tight junction 
formation and function.. The protein structure consists of cytoplasmic N- and C-termini, four 
transmembrane domains and two extracellular loops. Immunohistochemical analysis and 
differential expression studies between normal and cancerous tissues indicate that CLDN4 
expression is highly detectable in a variety of carcinomas, including pancreatic cancers. 
However, CLDN4 protein is detectable in normal breast, prostate, bladder, and 
gastrointestinal mucosa, although its expression is substantially less intense than that seen in 
cancer tissue samples (83). Recently a chimeric (mouse/human) anti-CLDN4 has been 
evaluated in preclinical studies (84). mAb KM3934 induced dose-dependent antibody-
dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, and 
significantly inhibited tumor growth in CFPAC-1 xenografted SCID mice indicating that 
CDLN4 might be a valuable pancreatic tumor target. 
Feto-acinar pancreatic protein (FAPP) is present at the cell surface of human pancreatic 
tumoral tissues. A murine antibody, mAb16D10, recognizing the O-glycosylated COOH-
terminal domain of FAPP, has been developed. In a recent study (85), this mAb stained 22 
tumoral tissues over the 22 tested, independently of the tissue pretreatment (frozen sections or 
formalin-fixed, paraffin-embedded sections) and presented a unique specificity for 
membranes of neoplastic cells. Furthermore, the mAb16D10 did not react with all non 
pancreatic tumoral and normal tissues tested. Moreover, i.p. injections of mAb16D10 in mice 
xenotransplanted with human pancreatic tumoral SOJ-6 cells decreased the growth rate of the 
established tumor (86), indicating that this target might be of interest for antibody based 
pancreatic cancer therapy. 
Conclusion 
There is an obvious need for new therapies in pancreatic cancers. Therapeutic antibodies have 
been successful in a number of malignancies, but results obtained on pancreatic cancer 
treatments have so far been extremely frustrating, with all phase III clinical trials leading to 
failure. However, recent years have seen the emergence of new antibody formats such as 
bispecific antibodies and the discovery of highly specific tumor markers. These advances 
should yield major improvements in a near future and should ultimately greatly impact the 
treatment of this devastating disease. 
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Table 1 : Antibodies approved for therapeutic use in cancer 
Generic name Trade name Antibody format Antigen Approved indication 9FDA  approval 9EMEA approval 
Rituximab
1
 Mabthera  chimeric, IgG1  CD20 CD20-positive B-cell non-Hodgkin’s lymphoma 97/11/26 98/06/02 
Trastuzumab Herceptin Humanized, IgG1 HER2/Neu Metastatic breast cancer 98/09/25 00/08/28 
Gemtuzumab
2
 Mylotarg humanized, IgG4 CD33 CD33 positive acute myeloid leukemia 00/05/17 NA 
Alemtuzumab
3
 Mabcampath humanized, IgG1 CD52 B-cell chronic lymphocytic leukemia 01/05/07 01/07/06 
Ibritomomab
4
 Zevalin 
90
Y mouse, IgG1 CD20  B-cell non-Hodgkin's lymphoma 02/02/19 04/01/16 
Tositumomab
4, 5
 Bexxar 
131
I  mouse, IgG2a CD20  CD20-positive B-cell non-Hodgkin’s lymphoma 03/06/27 NA 
Cetuximab Erbitux chimeric, IgG1 EGFR Metastatic colorectal and head and neck carcinoma 04/02/12 04/06/29 
Bevacizumab
6
 Avastin humanized, IgG1 VEGF-A Metastatic colon and rectum and non-small cell lung cancer 04/02/26 05/01/12 
Panitumumab
7
 Vectibis human, IgG2 EGFR Metastatic colorectal carcinoma 06/09/27 07/12/19 
Catumaxomab
8
 Removab mouse,IgG2a/rat IgG2b EpCAM/CD3 Malignant ascites NA 09/05/13 
Ofatumumab
7
 Arzerra human, IgG1 CD20 B-cell chronic lymphocytic leukemia 09/10/26 NA
 
 
1  
Rituximab is commercialized under the trade name Rituxan in USA.  
2
  Gemtuzumab “ozogamicine“ is coupled to calicheamicin, an antitumoral antibiotic. 
3
  Alemtuzumab is commercialized under the trade name Campath in USA. 
4
  Ibritomomab “tiuxetan“ and Tositumomab are coupled to radioisotopes. 
5
  All approved antibodies have a kappa light chain kappa except Tositumomab which has a lambda light chain.  
6
  Bevacizumab has also been recently approved for breast (February, 2008), renal (jully, 2009) cancers and glioblastoma (may, 2009). 
7
  Human antibodies obtained from humanized mice. 
8
  Catumaxomab is a bispecific antibody obtained from mouse and rat monoclonal antibodies. 
9
  Year/Month/Day; NA: Not approved.  
